Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826930 · ClinicalTrials.gov registry record · Phase 1
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
A Phase 1 study, sponsored by Diffusion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00826930 is a Phase 1 study that was terminated before completion, run by Diffusion Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT00826930, a Phase 1 study, was terminated before completion, sponsored by Diffusion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma. The proposed clinical indication for TSC is a radiation sensitizer for the treatment of cancerous tumors.
Interventions
- DRUG Trans Sodium Crocetinate (TSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826930
The ClinicalTrials.gov registry entry for NCT00826930 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diffusion Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trans Sodium Crocetinate (TSC) is the first listed.
NCT00826930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826930 about?
NCT00826930 is a clinical study titled "Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma". The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma. The proposed clinical indication for TSC is a radiation sensitizer for the treatment of cancerous tumors.
What is the current status of trial NCT00826930?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00826930?
The interventions under investigation include: Trans Sodium Crocetinate (TSC) (DRUG).
Who is sponsoring clinical trial NCT00826930?
This trial is sponsored by Diffusion Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.